Clinical trials
Lung Neoplasms trials in Taiwan with unknown status
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
38 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2002 | 1 |
| 2004 | 1 |
| 2005 | 2 |
| 2007 | 2 |
| 2008 | 1 |
| 2009 | 2 |
| 2010 | 5 |
| 2011 | 2 |
| 2012 | 1 |
| 2013 | 2 |
| 2014 | 1 |
| 2015 | 3 |
| 2016 | 4 |
| 2017 | 1 |
| 2019 | 4 |
| 2020 | 1 |
| 2021 | 1 |
| 2023 | 2 |
| 2024 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Unknown status | 38 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| National Taiwan University Hospital | 21 |
| Taipei Medical University WanFang Hospital | 3 |
| Chang Gung Memorial Hospital | 2 |
| National Taiwan University Hospital Hsin-Chu Branch | 2 |
| Cathay General Hospital | 1 |
| Chung Shan Medical University | 1 |
| E-DA Hospital | 1 |
| Far Eastern Memorial Hospital | 1 |
| Kaohsiung Medical University Chung-Ho Memorial Hospital | 1 |
| National Health Research Institutes, Taiwan | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Lung Neoplasms | 38 |
| Tuberculosis | 3 |
| Carcinoma, Non-Small-Cell Lung | 2 |
| Dyspnea | 2 |
| Liver Neoplasms | 2 |
| Neoplasms | 2 |
| Adenocarcinoma | 1 |
| Adenocarcinoma of Lung | 1 |
| Brain Neoplasms | 1 |
| Breast Neoplasms | 1 |
Trials
Showing 1 to 25 of 38. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.